Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

Type 1 Diabetes Clinical Trial

Official title: Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

Status Completed

Clinical Trial Summary

This purpose of this study is to determine if activation of a person's immune system in the small intestine could be a contributing cause of Type 1 Diabetes.

Clinical Trial Description

There is a large body of literature hinting at a role of the gut in Type One Diabetes (T1D) pathogenesis. However, to the best of our knowledge there is no definitive evidence to date conclusively demonstrating a link. The only way to test this hypothesis is to have access to the intestinal tissue of T1D patients at very early stages when beta-islet cell destruction is still ongoing. Furthermore, to prepare for large prospective studies it is critical to determine whether there is a peripheral blood signature for intestinal inflammation. Finally, because enteroviral infections have been implicated in T1D pathogenesis, this study provides a unique opportunity to determine whether there is a dysregulated response to innate stimuli associated with viral infections and whether evidence of transcriptional signatures indicative of viral infections in the gut is correlated with disease. Finally, we will take advantage of this pilot study to collect samples that can be used for microbiome, virome and metabolic studies. ;

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Inflammation
• Type 1 Diabetes

• NCT number: NCT01940835
• Study type: Observational
• Source: Mayo Clinic
• Status: Completed
• Start date: September 2013
• Completion date: June 19, 2019